A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
Recruiting · NCT07281001 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.
What this trial is about
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients aged over 18 years old.
- Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
- Patients has received Trastuzumab Deruxtecan
- Available medical history.
Exclusion criteria
- Incomplete medical history.
- Pregnancy or breast-breeding
Where it is running
1 location listed.
- Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation - Moscow, Russia